About The Study: The findings of this study suggest that patients with cancer had a disparate burden of COVID-19 mortality during the winter Omicron wave compared with the general U.S. population. With the emergence of new, immune-evasive SARS-CoV-2 variants, many of which are anticipated to be resistant to monoclonal antibody treatments, strategies to prevent COVID-19 transmission should remain a high priority.
Authors: Chi-Fu Jeffrey Yang, M.D., of Massachusetts General Hospital in Boston, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamaoncol.2023.3066)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2023.3066?guestAccessKey=85118918-ccbf-4525-bfd9-90914fdc12ad&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=083123
JAMA Oncology